MediciNova Inc., a California-based biopharmaceutical company, is focused on the development of innovative and small molecule therapeutics to address serious diseases with unmet medical needs in the US. The company's primary drug in development is MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent designed to treat neurological and other disorders. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, degenerative cervical myelopathy, glioblastoma, chemotherapy-induced peripheral neuropathy, as well as substance dependence and addiction. In addition to MN-166, MediciNova's product pipeline boasts additional therapeutic candidates, including MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist developed to treat acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound designed to treat various fibrotic and non-alcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent developed to treat solid tumor cancers. MediciNova has formed collaboration agreements with several pharmaceutical companies, including Kissei Pharmaceutical Co., Kyorin Pharmaceutical Co., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd., in support of their efforts to bring novel therapeutics to market. The company was established in 2000 and is headquartered in La Jolla, California.
MediciNova Inc.'s ticker is MNOV
The company's shares trade on the NASDAQ stock exchange
They are based in La Jolla, California
There are 1-10 employees working at MediciNova Inc.
It is http://www.medicinova.com
MediciNova Inc. is in the Healthcare sector
MediciNova Inc. is in the Biotechnology industry
The following five companies are MediciNova Inc.'s industry peers: